Fingolimod does not enhance cerebellar remyelination in the cuprizone model

• DOI: 10.1016/j.jneuroim.2015.06.006
• Publication Date: 2015-06-19T12:57:17Z
• Authors: Maria Nordheim Alme; Agnes E. Nystad; Lars Bø; Kjell-Morten Myhr; Christian A. Vedeler; Stig Wergeland; Øivind Torkildsen
• Keywords: Remyelination

Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but vivo animal not detected any positive effect on cerebral remyelination. The discrepant findings could be a result different mechanisms underlying and cuprizone model de- was used to evaluate whether had an impact vivo. We did remyelination, number mature oligodendrocytes, microglia or astrocytes when fed after exposure.